Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes
(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, data from the open-label...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.